eMed has been valued at over US$2bn after completing a US$200m Series A round, marking a new milestone for the Miami-based digital healthcare startup.
Led by AON Consulting, the round’s investors included retired NFL star Tom Brady, who became the company’s chief wellness officer earlier this year, and Linda Yaccarino, former chief executive of X and current eMed chief executive.
“I believe eMed’s empathic agentic AI platform, combined with the strength of its people and partners, represents a true winning formula,” Brady said.
“That conviction is why I’ve chosen to invest both my time as Founding Chief Wellness Officer and my capital in the company.”
The company said it will use the funding to develop its agentic AI platform and to fund a new “capitated model” designed to help employers with healthcare costs, especially as they relate to GLP-1 diabetes and weight loss drugs, the focus of the eMed website.
“GLP-1 medications are the most requested workplace benefit, yet only one in five companies provide the benefit. eMed is changing that,” the release said.
“By achieving more than 90 per cent member adherence, more than double the industry norm, eMed’s program delivers what others cannot: employees who stay the course and see real results, including an average weight loss of 21 pounds, with 99 per cent seeing improvement in at least one key biomarker within six months.”
“The raise confirms eMed momentum and establishes us as the definitive company for population health and helping employers break the runaway health care costs and break their cost curve,” Yaccarino told FOX Business.
